newsfilter
← Latest News
PR Newswire·

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF®...